Table 3. MVARC and 30-day outcomes of patients undergoing TMVI.

TMVI (N=38)
Myocardial infarction	1 (2.6)
Disabling stroke	0 (0.0)
Renal failure ≥AKIN stage 2	3 (7.9)
Major access site complication	9 (23.7)
Major/life-threatening bleeding	7 (18.4)
Procedural mortality	1 (2.6)
In-hospital mortality	3 (7.9)
MVARC technical success	33 (86.8)
MVARC device success	26 (68.4)
AKIN: Acute Kidney Injury Network; MVARC: Mitral Valve Academic Research Consortium; TMVI: transcatheter mitral valve implantation